Table 1.
Antibiotic susceptibility profiles of RT106 clinical isolates (this study).
| Strain | Minimum inhibitory concentration (MIC) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Teicoplanin | Cefotaxime | Clindamycin | Erythromycin | Levofloxacin | Moxifloxacin | Tetracycline | Vancomycin | Metronidazole | |
| 0.016–256 mcg/mL | 0.002–32 mcg/mL | 0.016–256 mcg/mL | 0.016–256 mcg/mL | 0.002–32 mcg/mL | 0.002–32 mcg/mL | 0.016–256 mcg/mL | 0.016–256 mcg/mL | 0.016–256 mcg/mL | |
| GV371 | 0.125 | > 32a | 4a | > 256b | 4 | 3 | 0.50 | 0.75 | 0.50 |
| GV423 | 0.125 | > 32a | 6a | > 256b | 4 | 3 | 0.50 | 1.00 | 0.50 |
| GV432 | 0.125 | > 32a | 4a | > 256b | 4 | 2 | 0.09 | 1.00 | 0.38 |
| GV597 | 0.094 | > 32a | 4a | 2 | 12b | 4a | 0.38 | 0.75 | 0.38 |
| GV453 | 0.125 | > 32a | 4a | 1.50 | 4 | 4a | 0.50 | 1.00 | 0.50 |
| GV587 | 0.125 | > 32a | 6a | 1 | 4 | 4a | 0.50 | 0.75 | 0.38 |
| GV642 | 0.125 | > 32a | 4a | 1.50 | 4 | 6a | 0.38 | 0.75 | 0.50 |
| GV364 | 0.125 | > 32a | 4a | 1 | 6 | 2 | 0.50 | 1.00 | 0.50 |
| GV375 | 0.125 | > 32a | 4a | 1 | 6 | 2 | 0.38 | 0.50 | 0.75 |
| GV377 | 0.125 | > 32a | 4a | 2 | 4 | 3 | 0.38 | 0.75 | 0.75 |
| GV415 | 0.125 | > 32a | 4a | 1 | 6 | 3 | 0.50 | 1.00 | 0.50 |
| GV421 | 0.125 | > 32a | 4a | 1 | 4 | 2 | 0.38 | 0.75 | 0.75 |
| GV425 | 0.125 | > 32a | 6a | 0.75 | 4 | 3 | 0.06 | 0.75 | 0.19 |
| GV426 | 0.094 | > 32a | 4a | 1.50 | 6 | 3 | 0.50 | 0.75 | 0.50 |
| GV524 | 0.125 | > 32a | 4a | 0.75 | 4 | 3 | 0.50 | 0.75 | 0.38 |
| GV576 | 0.125 | > 32a | 4a | 1 | 4 | 3 | 0.38 | 0.75 | 0.50 |
| GV589 | 0.094 | > 32a | 4a | 1 | 4 | 2 | 0.38 | 0.75 | 0.50 |
| GV753 | 0.125 | > 32a | 6a | 1 | 4 | 3 | 0.38 | 0.75 | 0.50 |
| GV599 | 0.094 | > 32a | 3 | 1 | 4 | 3 | 0.38 | 0.50 | 0.38 |
| GV457 | 0.094 | > 32a | 3 | 1 | 4 | 3 | 0.13 | 0.75 | 0.38 |
| GV515 | 0.125 | > 32a | 3 | 1 | 4 | 2 | 0.38 | 1.00 | 0.50 |
| 630 | 0.064 | > 32a | > 256b | > 256b | 4 | 3 | 64b | 1.50 | 0.25 |
| VPI | 0.032 | > 32a | 4a | 1 | 3 | 1 | 0.38 | 1.00 | 0.25 |
| T-7 | 0.064 | > 32a | 3 | 1 | 4 | 3 | 0.50 | 1.00 | 0.50 |
| BI-1 | 0.064 | > 32a | 2 | 1 | 4 | 2 | 0.38 | 1.50 | 0.25 |
| CLSI Breakpoints (mcg/mL) | NA | ≥ 64 (Resistant) | ≥ 8 (Resistant) | NA | NA | ≥ 8 (Resistant) | ≥ 16 (Resistant) | NA | ≥ 32 (Resistant) |
| NA | 32 (Intermediate Resistance) | 4 (Intermediate Resistance) | NA | NA | 4 (Intermediate Resistance) | 8 (Intermediate Resistance) | NA | 16 (Intermediate Resistance) | |
| NA | ≤ 16 (Susceptible) |
≤ 2 (Susceptible) |
NA | NA |
≤ 2 (Susceptible) |
≤ 4 (Susceptible) |
NA |
≤ 8 (Susceptible) |
|
| EUCAST Breakpoints (mcg/mL) | NA | NA | NA | NA | NA | NA | NA | ≥ 2 (Resistant) | ≥ 2 (Resistant) |
| NA | NA | NA | NA | NA | NA | ≤ 2(Susceptible) | ≤ 2(Susceptible) | ||
Numbers in bold font represent high MIC values.
aDenotes that strain is moderately resistant to specific antibiotics.
bDenotes that strain is highly resistant to specific antibiotics.